EuBiologics Co., Ltd. (KOSDAQ:206650)

Market Cap	470.06B +15.3%
Revenue (ttm)	96.04B +62.4%
Net Income	24.87B
EPS	n/a
Shares Out	36.72M
PE Ratio	18.90
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	304,019
Average Volume	266,614
Open	13,100
Previous Close	13,150
Day's Range	12,770 - 13,150
52-Week Range	10,940 - 17,700
Beta	0.53
RSI	39.69
Earnings Date	Apr 3, 2026

About EuBiologics

EuBiologics Co., Ltd., a biopharmaceutical company, focuses on developing vaccines against global pandemic and bacterial vaccines primarily in South Korea. It offers inactivated oral cholera vaccine under the Euvichol, Euvichol-Plus, and Euvichol-S names; and EuCorVac-19, a recombinant protein vaccine. The company also provides EcML that is used as a vaccine adjuvant, directly activating antigen presenting cell expressing TLR 4 agonist, stimulating the production of cytokines and co-stimulatory molecules. In addition, it offers carrier protein ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 206650